{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:38Z","timestamp":1791260738381,"version":"4.1.0"},"reference-count":28,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To assess 1-year persistence and adherence rates with drug therapy among patients with fibromyalgia (FM) and to identify factors associated with therapy discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>This retrospective, cohort study included members \u2265 21 years old from the Maccabi Healthcare Services, a large health maintenance organization in Israel, who were diagnosed with FM from 2008 through 2011. Medications of interest included the anticonvulsant pregabalin, antidepressants [selective serotonin reuptake inhibitor (SSRI), serotonin\/norepinephrine reuptake inhibitor (SNRI)], and tricyclic antidepressants (TCA). Time to treatment discontinuation and proportion of days covered (PDC) with FM-specific therapies during the year from first dispensed were analyzed. PDC &lt; 20% was considered low adherence and PDC \u2265 80% was considered high adherence. Logistic regression models were constructed for multivariable analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Overall, 3932 patients with FM were included; 88.7% were female. Pre-diagnosis use of medication of interest was documented in 41% of the study population. Of the remaining 2312 patients, 56.1% were issued a prescription, 45.0% were dispensed at least 1 medication in the year following diagnosis, and only 28.8% had prescriptions filled twice within the first year from diagnosis. Among newly prescribed patients, 1-year discontinuation was highest for TCA (91.0%) and lowest for SSRI\/SNRI antidepressants (73.7%). Over half of the patients (60.5%) had fewer than 20% of the days covered by any medication during the year and only 9.3% were very adherent (PDC \u2265 80%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>This study clearly shows that in an Israeli \u201creal-life\u201d population of patients with FM, persistence and adherence with FM therapy in the year following diagnosis is remarkably low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.170098","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T20:20:23Z","timestamp":1501618823000},"page":"1499-1506","source":"Crossref","is-referenced-by-count":48,"title":["Adherence and Persistence with Drug Therapy among Fibromyalgia Patients: Data from a Large Health Maintenance Organization"],"prefix":"10.3899","volume":"44","author":[{"given":"Dana","family":"Ben-Ami Shor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia","family":"Weitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Bar-On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varda","family":"Shalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"issue":"Suppl 96","key":"2018112909372744000_44.10.1499.1","first-page":"S145","article-title":"One year in review 2016: fibromyalgia","volume":"34","author":"Bazzichi","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909372744000_44.10.1499.2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8509-4"},{"key":"2018112909372744000_44.10.1499.3","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-013-0356-5"},{"key":"2018112909372744000_44.10.1499.4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.autrev.2011.10.018","article-title":"Is fibromyalgia a discrete entity?","volume":"11","author":"Ablin","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2018112909372744000_44.10.1499.5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AJP.0000000000000354","article-title":"Fibromyalgia and chronic pain syndromes: a white paper detailing current challenges in the field","volume":"32","author":"Arnold","year":"2016","journal-title":"Clin J Pain"},{"key":"2018112909372744000_44.10.1499.6","doi-asserted-by":"crossref","first-page":"528952","DOI":"10.1155\/2013\/528952","article-title":"Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines","volume":"2013","author":"Fitzcharles","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"2018112909372744000_44.10.1499.7","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-013-0016-9"},{"key":"2018112909372744000_44.10.1499.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.07.048"},{"key":"2018112909372744000_44.10.1499.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"2018112909372744000_44.10.1499.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes431"},{"key":"2018112909372744000_44.10.1499.11","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2101"},{"key":"2018112909372744000_44.10.1499.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00431.x"},{"key":"2018112909372744000_44.10.1499.13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/acr.22071","article-title":"Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2018112909372744000_44.10.1499.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep176"},{"key":"2018112909372744000_44.10.1499.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000336"},{"key":"2018112909372744000_44.10.1499.16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bjd.13850","article-title":"Adherence to statins and the risk of psoriasis: a population-based cohort study","volume":"173","author":"Chodick","year":"2015","journal-title":"Br J Dermatol"},{"key":"2018112909372744000_44.10.1499.17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12026-014-8603-3","article-title":"No male predominance in offspring of women with rheumatoid arthritis or systemic lupus erythematosus","volume":"60","author":"Dar","year":"2014","journal-title":"Immunol Res"},{"key":"2018112909372744000_44.10.1499.18","unstructured":"Burck L . Characterization and classification of geographical units by the socio-economic level of the population. Tsibel N , editor. Israel: Central Bureau of Statistics; 2013."},{"key":"2018112909372744000_44.10.1499.19","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.2011.557362","article-title":"Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists","volume":"2","author":"Seidel","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"2018112909372744000_44.10.1499.20","first-page":"263","article-title":"Treatment patterns associated with ACR-recommended medications in the management of fibromyalgia in the United States","volume":"22","author":"Liu","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2018112909372744000_44.10.1499.21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JPR.S31800","article-title":"Predictors of duloxetine adherence and persistence in patients with fibromyalgia","volume":"5","author":"Cui","year":"2012","journal-title":"J Pain Res"},{"key":"2018112909372744000_44.10.1499.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.12.017"},{"key":"2018112909372744000_44.10.1499.23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/pme.12168","article-title":"Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study","volume":"14","author":"Robinson","year":"2013","journal-title":"Pain Med"},{"key":"2018112909372744000_44.10.1499.24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/j.1532-2149.2012.00234.x","article-title":"Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia","volume":"17","author":"Wolfe","year":"2013","journal-title":"Eur J Pain"},{"key":"2018112909372744000_44.10.1499.25","first-page":"CD012188","article-title":"Gabapentin for fibromyalgia pain in adults","volume":"1","author":"Cooper","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909372744000_44.10.1499.26","first-page":"CD011790","article-title":"Pregabalin for pain in fibromyalgia in adults","volume":"9","author":"Derry","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909372744000_44.10.1499.27","first-page":"CD010292","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome","volume":"1","author":"H\u00e4user","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909372744000_44.10.1499.28","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2013.00341.x"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:24:12Z","timestamp":1543501452000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,1]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.3899\/jrheum.170098"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170098","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}